SKLB1028

DRUG6 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Advanced Solid TumorsHealthy Subjects

Phase 1

A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Acute Myeloid Leukemia

Start: 2016-05-31End: 2018-01-31Target: 18Updated: 2016-08-09

A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Healthy Subjects

Start: 2021-06-07End: 2021-11-30Updated: 2021-10-06

A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy Subjects

CompletedNCT05070195

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Healthy Subjects

Start: 2021-06-07End: 2021-07-09Updated: 2021-10-07

A Study of SKLB1028 in Patients With Advanced Solid Tumor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Solid Tumors

Start: 2021-10-31End: 2023-10-31Target: 98Updated: 2021-10-11

A Dose Escalation and Food Effect Study of SKLB1028 in Healthy Subjects

CompletedNCT05109663

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Healthy Subjects

Start: 2021-04-14End: 2021-06-30Updated: 2021-11-17

Phase 3

A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Acute Myeloid Leukemia (AML)

Start: 2021-03-24End: 2025-12-31Target: 315Updated: 2021-11-02

Related Papers

Preliminary Analysis Results of a Phase I Study of the FLT3 Inhibitor SKLB1028 in Patients with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Blood2019-11-13